Zura Bio Ltd Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Zura Bio Limited on November 30, 2023. The filing discloses the appointment of a new executive officer effective November 27, 2023. Zura Bio is an emerging growth company incorporated in the Cayman Islands with principal executive offices in Henderson, Nevada.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Dr. Kiran Nistala as Executive Vice President. Dr. Nistala brings nearly two decades of experience in translational medicine and clinical trial design, with previous senior roles at AstraZeneca and GlaxoSmithKline specializing in immunology, rheumatology, and dermatology.
Compensation and Equity Arrangements
- Base Salary: GBP 320,000 annually.
- Performance Bonus: Discretionary annual bonus with a target of 40% of the base salary, subject to review by the CEO, HR, and the Board.
- Equity Grant: The Company will recommend the grant of 350,000 share options priced at the closing price on the grant date.
- Vesting Schedule: 25% vests on the first anniversary of the commencement date; the remaining 75% vests monthly over the subsequent 36 months (1/36th per month), contingent on continued employment.
- Termination: Employment may be terminated for cause immediately without notice or further payment liability.
Investor Verification Checklist
- Verify the final grant date and exercise price of the 350,000 share options, as the filing states they will be priced at the closing price on the date of grant.
- Confirm the specific vesting start date based on the November 27, 2023 commencement date.
- Review the attached Service Agreement (Exhibit 10.1) for any redacted terms regarding non-compete clauses or additional benefits.
- Monitor future filings for the actual issuance of the equity grant and any changes to the discretionary bonus targets.